Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
Following equity shortcomings, Vaccinex ends its journey as a public company after six and a half years.
Following equity shortcomings, Vaccinex ends its journey as a public company after six and a half years.
What's Your Reaction?
